Analysis of Cardiovascular Thromboembolic Events With Etoricoxib. Joel Schiffenbauer, M.D. DAAODP, ODE V February 17, 2005. Etoricoxib. NDA indications include: OA, CLBP, RA, AS, acute gout, acute pain, dysmenorrhea Proposed doses: 60 and 90 mg chronically and 120 mg acutely
Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.
Analysis of Cardiovascular Thromboembolic Events With Etoricoxib
Joel Schiffenbauer, M.D.
DAAODP, ODE V
February 17, 2005
CV/TE Events in NDA
CV Events in EDGE Study
13% celecoxib; 5% valdecoxib)